In vitro experiments indicated that interferon gamma (IFNγ), a key immune cytokine in MSI tumours, downregulates FABP1 expression, while activation of PPARγ (with rosiglitazone) can restore it, suggesting a regulatory loop (Figure 5) influenced by inflammatory signalling. The gene discussed is FABP1; the disease is neoplasm.